Journal of Lipid Research, Vol 35, 982-992, Copyright © 1994 by Lipid Research, Inc.

ARTICLES

Comparative effects of purified apolipoproteins A-I, A-II, and A-IV on cholesteryl ester transfer protein activity

V Guyard-Dangremont, L Lagrost and P Gambert
Laboratoire de Biochimie des Lipoproteines, INSERM CJF 93-10, Faculte de Medecine, Dijon, France.

The aim of the present study was to determine in vitro the effects of various purified apolipoproteins (apo) on the activity of the cholesteryl ester transfer protein (CETP). It appeared that the ability of apoA-I, A-II, and A-IV to modulate the CETP-mediated transfer of radiolabeled cholesteryl esters between low density lipoproteins (LDL) and high density lipoproteins (HDL) was markedly influenced by the final apolipoprotein:lipoprotein ratio in incubation mixtures. At low apolipoprotein:lipoprotein ratio, the rate of radiolabeled cholesteryl esters transferred from HDL3 to LDL was significantly increased in the presence of apoA-I and apoA-IV. Under similar conditions, the rate of radiolabeled cholesteryl esters transferred from LDL to HDL3 was increased in the presence of apoA-I while apoA-IV had no significant effects. At high apolipoprotein:lipoprotein ratio, the ability of apoA- I and apoA-IV to enhance the rate of radiolabeled cholesteryl esters transferred either from HDL3 to LDL or from LDL to HDL3 was considerably reduced. At the highest apolipoprotein:lipoprotein ratio studied, apoA-I and A-IV became inhibitors of the CETP-mediated transfer reaction. Interestingly, apoA-II differed markedly from other apolipoproteins as, even at a low apolipoprotein:lipoprotein ratio, it significantly inhibited CETP activity as measured either from HDL3 to LDL or from LDL to HDL3. The inhibition by apoA-II was concentration- dependent and, at the highest apolipoprotein:lipoprotein ratio studied, cholesteryl ester transfer activity was totally suppressed. The possibility of a direct interaction between CETP and the two major HDL apolipoproteins, apoA-I and apoA-II, was further investigated by combining crosslinking and immunoblotting techniques. Whereas CETP alone had an apparent molecular mass of 76,000 +/- 3,100 Da, crosslinking reactions in incubation mixtures containing CETP and either apoA-I or apoA-II revealed the appearance of additional protein bands with apparent molecular masses of 99,600 +/- 6,100 and 86,900 +/- 4,500 Da, respectively. These complexes corresponded to the association of one molecule of CETP with one molecule of apoA-I or apoA-II. Interestingly, the mass concentrations of apoA-II needed to produce visible CETP-apolipoprotein complexes appeared to be about ten times higher as compared with apoA-I, suggesting that CETP may have a lower affinity for apoA-II than for apoA-I. In conclusion, data from the present study indicate that apolipoproteins A-I, A-II, and A-IV could be potent modulators of the CETP-mediated transfer of cholesteryl esters between HDL and LDL fractions.(ABSTRACT TRUNCATED AT 400 WORDS)
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Lee-Rueckert, R. Vikstedt, J. Metso, M. Jauhiainen, and P. T. Kovanen Association of cholesteryl ester transfer protein with HDL particles reduces its proteolytic inactivation by mast cell chymase J. Lipid Res., February 1, 2008; 49(2): 358 - 368. [Abstract] [Full Text] [PDF]

				B. C.H. Kwan, F. Kronenberg, S. Beddhu, and A. K. Cheung Lipoprotein Metabolism and Lipid Management in Chronic Kidney Disease J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1246 - 1261. [Full Text] [PDF]

				A. Lingenhel, K. Lhotta, U. Neyer, I. M. Heid, B. Rantner, M. F. Kronenberg, P. Konig, A. von Eckardstein, M. Schober, H. Dieplinger, et al. Role of the kidney in the metabolism of apolipoprotein A-IV: influence of the type of proteinuria J. Lipid Res., September 1, 2006; 47(9): 2071 - 2079. [Abstract] [Full Text] [PDF]

				L. Dumont, T. Gautier, J.-P. P. de Barros, H. Laplanche, D. Blache, P. Ducoroy, J. Fruchart, J.-C. Fruchart, P. Gambert, D. Masson, et al. Molecular Mechanism of the Blockade of Plasma Cholesteryl Ester Transfer Protein by Its Physiological Inhibitor Apolipoprotein CI J. Biol. Chem., November 11, 2005; 280(45): 38108 - 38116. [Abstract] [Full Text] [PDF]

				G. C. Shearer, J. W. Newman, B. D. Hammock, and G. A. Kaysen Graded Effects of Proteinuria on HDL Structure in Nephrotic Rats J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1309 - 1319. [Abstract] [Full Text] [PDF]

				B. Ezeh, M. Haiman, H. F. Alber, B. Kunz, B. Paulweber, A. Lingenhel, H.-G. Kraft, F. Weidinger, O. Pachinger, H. Dieplinger, et al. Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls J. Lipid Res., August 1, 2003; 44(8): 1523 - 1529. [Abstract] [Full Text] [PDF]

				T. Gautier, D. Masson, M. C. Jong, L. Duverneuil, N. Le Guern, V. Deckert, J.-P. P. de Barros, L. Dumont, A. Bataille, Z. Zak, et al. Apolipoprotein CI Deficiency Markedly Augments Plasma Lipoprotein Changes Mediated by Human Cholesteryl Ester Transfer Protein (CETP) in CETP Transgenic/ApoCI-knocked Out Mice J. Biol. Chem., August 23, 2002; 277(35): 31354 - 31363. [Abstract] [Full Text] [PDF]

				R. B. Weinberg, R. A. Anderson, V. R. Cook, F. Emmanuel, P. Denefle, A. R. Tall, and A. Steinmetz Interfacial Exclusion Pressure Determines the Ability of Apolipoprotein A-IV Truncation Mutants to Activate Cholesterol Ester Transfer Protein J. Biol. Chem., June 7, 2002; 277(24): 21549 - 21553. [Abstract] [Full Text] [PDF]

				F. Ferrer, E. Bigot-Corbel, P. N'Guyen, M. Krempf, and J.-M. Bard Quantitative Measurement of Lipoprotein Particles Containing Both Apolipoprotein AIV and Apolipoprotein B in Human Plasma by a Noncompetitive ELISA Clin. Chem., June 1, 2002; 48(6): 884 - 890. [Abstract] [Full Text] [PDF]

				F. Kronenberg, E. Kuen, E. Ritz, P. Konig, G. Kraatz, K. Lhotta, J. F. E. Mann, G. A. Muller, U. Neyer, W. Riegel, et al. Apolipoprotein A-IV Serum Concentrations Are Elevated in Patients with Mild and Moderate Renal Failure J. Am. Soc. Nephrol., February 1, 2002; 13(2): 461 - 469. [Abstract] [Full Text] [PDF]

				B. Verges, B. Guerci, V. Durlach, C. Galland-Jos, J. L. Paul, L. Lagrost, and P. Gambert Increased plasma apoA-IV level is a marker of abnormal postprandial lipemia: a study in normoponderal and obese subjects J. Lipid Res., December 1, 2001; 42(12): 2021 - 2029. [Abstract] [Full Text] [PDF]

				R. M. Weggemans, P. L. Zock, S. Meyboom, H. Funke, and M. B. Katan Apolipoprotein A4-1/2 polymorphism and response of serum lipids to dietary cholesterol in humans J. Lipid Res., October 1, 2000; 41(10): 1623 - 1628. [Abstract] [Full Text]

				F. Kronenberg, M. Stuhlinger, E. Trenkwalder, F. S. Geethanjali, O. Pachinger, A. von Eckardstein, and H. Dieplinger Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease J. Am. Coll. Cardiol., September 1, 2000; 36(3): 751 - 757. [Abstract] [Full Text] [PDF]

				X. Wang, D. M. Driscoll, and R. E. Morton Molecular Cloning and Expression of Lipid Transfer Inhibitor Protein Reveals Its Identity with Apolipoprotein F J. Biol. Chem., January 15, 1999; 274(3): 1814 - 1820. [Abstract] [Full Text] [PDF]

				R. Carmena-Ramon, J. F. Ascaso, J. T. Real, J. M. Ordovas, and R. Carmena Genetic Variation at the ApoA-IV Gene Locus and Response to Diet in Familial Hypercholesterolemia Arterioscler. Thromb. Vasc. Biol., August 1, 1998; 18(8): 1266 - 1274. [Abstract] [Full Text] [PDF]

				P. J. Pussinen, M. Jauhiainen, J. Metso, L. E. Pyle, Y. L. Marcel, N. H. Fidge, and C. Ehnholm Binding of phospholipid transfer protein (PLTP) to apolipoproteins A-I and A-II: location of a PLTP binding domain in the amino terminal region of apoA-I J. Lipid Res., January 1, 1998; 39(1): 152 - 161. [Abstract] [Full Text]

				S. Jansen, J. Lopez-Miranda, J. Salas, J. M. Ordovas, P. Castro, C. Marin, M. A. Ostos, F. Lopez-Segura, J. A. Jimenez-Pereperez, A. Blanco, et al. Effect of 347-Serine Mutation in Apoprotein A-IV on Plasma LDL Cholesterol Response to Dietary Fat Arterioscler. Thromb. Vasc. Biol., August 1, 1997; 17(8): 1532 - 1538. [Abstract] [Full Text]

				M.N. Nanjee, J.R. Crouse, J.M. King, R. Hovorka, S.E. Rees, E.R. Carson, J.-J. Morgenthaler, P. Lerch, and N.E. Miller Effects of Intravenous Infusion of Lipid-Free Apo A-I in Humans Arterioscler. Thromb. Vasc. Biol., September 1, 1996; 16(9): 1203 - 1214. [Abstract] [Full Text]

				L. Lagrost, E. Florentin, V. Guyard-Dangremont, A. Athias, H. Gandjini, C. Lallemant, and P. Gambert Evidence for Nonesterified Fatty Acids as Modulators of Neutral Lipid Transfers in Normolipidemic Human Plasma Arterioscler. Thromb. Vasc. Biol., September 1, 1995; 15(9): 1388 - 1396. [Abstract] [Full Text]

				T. Gautier, D. Masson, J.-P. P. de Barros, A. Athias, P. Gambert, D. Aunis, M.-H. Metz-Boutigue, and L. Lagrost Human Apolipoprotein C-I Accounts for the Ability of Plasma High Density Lipoproteins to Inhibit the Cholesteryl Ester Transfer Protein Activity J. Biol. Chem., November 22, 2000; 275(48): 37504 - 37509. [Abstract] [Full Text] [PDF]